Multibagger Pharma Stock To Keep Under Radar As Board Likely To Announce Stock Split

The stock is up by 75 per cent from its 52-week low of Rs 270.05 per share and gave multibagger returns of over 1,800 per cent in 5 years.

Jagsonpal Pharmaceuticals Limited informed that the meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, October 23, 2024 to consider and approve, inter-alia, the following:

1. Unaudited financial results of the company for the quarter and half year ended September 30, 2024.
2. Proposal for sub-division/split of existing equity shares of the company having a face value of Rs 5 each, fully paid up, in such manner as may be determined by the board of directors subject to the approval of equity shareholders of the company and other applicable approval(s) (if any).

Jagsonpal Pharmaceuticals Ltd., established in 1978, specializes in the manufacturing and trading of pharmaceutical products and active pharmaceutical ingredients. The company primarily focuses on women's healthcare needs through its Gynaecology and Orthopaedics segments. Additionally, it operates in major therapeutic sub-segments such as antibiotics, allergy management, immunity and cell protection, over-the-counter products, dermatology and paediatrics.

With a strong sales team of over 900 individuals, JPL has a nationwide presence and boasts 17 brands among the top 5 in their respective molecule categories. Interestingly, the company has outsourced its manufacturing processes through a loan licensing arrangement, allowing it to market formulations using external manufacturing units while supplying raw materials directly. Infinity Holdings currently holds a majority stake in JPL, becoming a joint promoter of the company.

The company has a market cap of over Rs 1,200 crore and has been maintaining a healthy dividend payout of 54.5 per cent. The stock is up by 75 per cent from its 52-week low of Rs 270.05 per share and gave multibagger returns of over 1,800 per cent in 5 years. Investors should keep an eye on this small-cap stock.

Disclaimer: The article is for informational purposes only and not investment advice. 

Also Read: This solar PV manufacturer could illuminate the primary market; can it double your investment?